TABLE 1.
Demographics for patients with metastatic colorectal cancer receiving FOLFOX or CUFOX treatment1
| FOLFOX | CUFOX | |
|---|---|---|
| Age, y | 68.3 (56–78) | 66.9 (53–77) |
| Resident in United Kingdom | ||
| Whole of life | 9 (100) | 17 (94.4) |
| Part of life | 0 (0) | 1 (5.6) |
| White British | 9 (100) | 18 (100) |
| Performance status2 | ||
| 0 | 6 (66.7) | 11 (61.1) |
| 1 | 3 (33.3) | 7 (38.9) |
| Tumor staging3 | ||
| M1a | 2 (22.2) | 9 (50) |
| M1b | 7 (77.8) | 5 (27.8) |
| M1c | 0 (0) | 4 (22.2) |
| Metastatic sites | ||
| Liver | 9 (100) | 17 (94.4) |
| Lung | 7 (77.8) | 6 (33.3) |
| Peritoneal | 0 (0) | 4 (22.2) |
| Adrenal | 1 (11.1) | 1 (5.6) |
| Portal hepatic nodes | 1 (11.1) | 0 (0) |
| Number of metastatic sites | ||
| 1 | 2 (22.2) | 10 (55.6) |
| 2 | 5 (55.6) | 7 (38.9) |
| 3 | 2 (22.2) | 1 (5.6) |
| Additional bevacizumab | 4 (44.4) | 8 (44.4) |
Values are mean (range) for age, and n (%) per arm for all other variables. The number of patients on FOLFOX and CUFOX in the intention-to-treat population was 9 and 18, respectively. CUFOX, folinic acid/5-fluorouracil/oxaliplatin + 2 g oral curcumin/d; FOLFOX, folinic acid/5-fluorouracil/oxaliplatin.
Eastern Cooperative Oncology Group definition: performance status of 0 = fully active, able to carry on all predisease performance without restriction; performance status of 1 = restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work.
All participants were stage 4, but with varying metastatic (M) disease.